*Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medical Center, University of Chicago
‡Department of Pathology, The University of Chicago Medical Center, Chicago, IL
†NRG Oncology Statistics and Data Management Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY
§Gynecologic Oncology Group Tissue Bank/NRG Oncology Biospecimen Bank, Biopathology Center, Research Institute at Nationwide Children’s Hospital, Columbus, OH
∥Gibbs Cancer Center and Research Institute, Spartanburg, SC
¶Division of Gynecologic Oncology, Penn State Hershey Medical Center, Hershey, PA
#The Women’s Healing Center, a division of HCA, Orlando, FL
**Division of Gynecological Oncology, Indiana University Hospital/Melvin and Bren Simon Cancer Center; Indianapolis, IN
††University of Arkansas for Medical Sciences, Little Rock, AR
✠Anthony G. Montag deceased.
Present address: Tatyana A. Grushko, PhD, Abbott Molecular Inc, Desplaines, IL.
Present address: Laura Monovich, MBA, Ohio State University Comprehensive Cancer Center, Columbus, OH.
Present address: Michael W. Method, MD, Eli Lilly & Co, Indianapolis, IN.
Supported by National Cancer Institute grants K12CA139160 and CTSA-ITM (CS UL1 RR024999) to T.A.G., CA 27469 to the Gynecologic Oncology Group (GOG) Administrative Office, CA 37517 to the GOG Statistical Office, 1U10 CA180822 to NRG Oncology, U10CA180868 to NRG Oncology Operations, U10 CA27469, U24 CA114793, U10 CA180868 to the Gynecologic GOG Tissue Bank, and P30 CA14599 to the University of Chicago Cancer Center and IHC core facility. O.I.O. was supported by EIF NWCRA.
Presented at the Society of Gynecologic Oncology (SGO) 45th Annual Meeting on Women’s Cancer (Tampa, FL, March 22 to 25, 2014).
Translational Trial Registration: 8013, NCI-2011-02245, CDR0000681556, NCT01164735.
The following Gynecologic Oncology Group member institutions participated in the primary treatment studies: Community Clinical Oncology Program, Penn State Milton S. Hershey Medical Center, Wayne State University/Karmanos Cancer Institute, Indiana University Hospital/Melvin and Bren Simon Cancer Center, Tufts-New England Medical Center, Women’s Cancer Center of Nevada, University of Alabama at Birmingham, Abington Memorial Hospital, University of Minnesota Medical Center-Fairview, Fred Hutchinson Cancer Research Center, University of Iowa Hospitals and Clinics, University of Texas Southwestern Medical Center, Rush University Medical Center, Cleveland Clinic Foundation, Stony Brook University Medical Center, Washington University School of Medicine, Cooper Hospital University Medical Center, Fox Chase Cancer Center, University of Virginia, and Moffitt Cancer Center and Research Institute.
T.A.G. carried out the FISH study, generated and analyzed data and illustrations and wrote study protocol, design and manuscript. V.L.F. performed statistical analyses and interpretation of the data, contributed to study protocol, design, figures, and tables and was major contributor in writing the manuscript. A.G.M. and M.A. performed study conception and design, acquisition of IHC data and critical revision. M.J.G. and L.M. provided key technical support, database, sample acquisition, and handling. N.C.R. provided sample acquisition and tumor morphology verification, study database, and critical revision. C.S., J.P.K., S.M.S., and M.W.M. provided database, sample acquisition, and handling. O.I.O. contributed to study conception, design, presentations, and intellectual and funding support, and was major contributor in writing the manuscript. G.F.F. contributed to protocol conception and design, interpretation of data, presentations, and was major contributor in writing the manuscript. M.J.B. contributed to study conception, design, presentations, and intellectual support. All authors read and approved the final manuscript.
V.L.F.: grants from NIH during the conduct of this study and additional funding from GOG Foundation Inc. outside the submitted work for other gynecologic clinical trials. S.M.S.: speakers Burea for GSK (Zejula), AstraZeneca (Olaparib), and Merk (Keytruda+lenvatanib). T.A.G.: current employee of Abbott. M.W.M.: current employee of Lilly and own Lilly stock. G.F.F.: Ad board for GSK, institutional PI for industry trials of Roche, Syros, GSK, Iovance, Sanofi, Sermonix, Incyte, Compugen, Abbvie, Eisai, Celldex, Astra Zeneca, Corcept, Merck, Plexxicon. The remaining authors declare no conflict of interest.
Reprints: Gini F. Fleming, MD, Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medical Center, University of Chicago, 5841 South Maryland Ave MC2115, Chicago, IL 60637 (e-mail: [email protected]).
